Roivant Sciences Ltd
ROIV
Company Profile
Business description
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.
Contact
50 Broadway
7th Floor
LondonSW1H 0BD
GBRT: +44 2074003347
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 March 2027
Employees
750
Stocks News & Analysis
stocks
A closer look at US tech earnings
How a handful of tech giants continue to shape market returns and what investors should watch next.
stocks
Cheap ASX energy share lifts earnings guidance on stronger output
Energy provider lifts earnings guidance on stronger power plant performance.
stocks
ASX listed bank overvalued despite strong earnings
Profit beats drive shares higher for Australia’s largest asset manager.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,909.60 | 42.50 | -0.47% |
| CAC 40 | 8,021.47 | 34.91 | -0.43% |
| DAX 40 | 24,177.73 | 172.55 | -0.71% |
| Dow JONES (US) | 49,704.47 | 95.31 | 0.19% |
| FTSE 100 | 10,219.14 | 50.29 | -0.49% |
| HKSE | 26,367.43 | 39.41 | -0.15% |
| NASDAQ | 26,274.13 | 27.05 | 0.10% |
| Nikkei 225 | 62,742.57 | 324.69 | 0.52% |
| NZX 50 Index | 13,080.33 | 130.15 | -0.99% |
| S&P 500 | 7,412.84 | 13.91 | 0.19% |
| S&P/ASX 200 | 8,670.70 | 40.60 | -0.47% |
| SSE Composite Index | 4,214.49 | 10.53 | -0.25% |